Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study
Tarih
2022Yazar
Pereyra, Cecilia
Blot, Stijn
Rello, Jordi
Paiva, Jose Artur
Vogelaers, Dirk
Arvaniti, Kostoula
Dimopoulos, George
Antonelli, Massimo
Blot, Koen
Creagh-Brown, Ben
Deschepper, Mieke
de Lange, Dylan
De Waele, Jan
DİKMEN, YALIM
Eckmann, Christian
Einav, Sharon
Francois, Guy
Fjeldsoee-Nielsen, Hans
Girardis, Massimo
Jovanovic, Bojan
Lindner, Matthias
Koulenti, Despoina
Labeau, Sonia
Lipman, Jeffrey
Lipovestky, Fernando
Makikado, Luis Daniel Umezawa
Maseda, Emilio
Mikstacki, Adam
Montravers, Philippe
Tomescu, Dana
Timsit, Jean-Francois
Üst veri
Tüm öğe kaydını gösterÖzet
Objective: To describe epidemiology and age-related mortality in critically ill older adults with intraabdominal infection.Methods: A secondary analysis was undertaken of a prospective, multi-national, observational study (Abdominal Sepsis Study, ClinicalTrials.gov #NCT03270345) including patients with intra-abdominal infection from 309 intensive care units (ICUs) in 42 countries between January and December 2016. Mortality was considered as ICU mortality, with a minimum of 28 days of observation when patients were discharged earlier. Relationships with mortality were assessed by logistic regression analysis.Results: The cohort included 2337 patients. Four age groups were defined: middle-aged patients [reference category; 40-59 years; n = 659 (28.2%)], young-old patients [60-69 years; n = 622 (26.6%)], middle old patients [70-79 years; n = 667 (28.5%)] and very old patients [ >80 years; n = 389 (16.6%)]. Secondary peritonitis was the predominant infection (68.7%) and was equally prevalent across age groups. Mortality increased with age: 20.9% in middle-aged patients, 30.5% in young-old patients, 31.2% in middle-old patients, and 44.7% in very old patients ( P 60 years was associated with mortality; patients aged >80 years had the worst prognosis. Comorbidities and overall disease severity further compromised survival. As all of these factors are non-modifiable, it remains unclear how to improve outcomes.(c) 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Bağlantı
http://hdl.handle.net/20.500.12627/188051https://doi.org/10.1016/j.ijantimicag.2022.106591
Koleksiyonlar
- Makale [92796]